Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B

Huang, Shang‐Chin; Kao, Jia‐Horng

doi:10.1016/j.jfma.2022.07.013

Cited by 16 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 10 , 11 However, several published studies showed an inverse association between hepatic steatosis and HBV replication. [12] , [13] , [14] Moreover, the risk of hepatocellular carcinoma was reduced in patients with CHB with hepatic steatosis. 15 , 16 However, the relationship between HBV infection and atherosclerosis remains inconclusive.…”

Section: Introductionmentioning

confidence: 98%

Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…Another factor is the influence of the co-existing metabolic dysfunction in patients with MAFLD, including obesity or DM, which are also the established risk factors for HCC occurrence in CHB [35][36][37] . In other words, the simple steatosis and metabolic dysfunction required for diagnosing MAFLD may have diverse effects on hepatic carcinogenesis exclusively in CHB patients (Figure 2) 38 . Therefore, strategies for optimal risk stratification and individualized management for those with concurrent MAFLD need to be developed in future studies.…”

Section: Inconclusive Results For Mafld and Risk Of Hbv-related Hccmentioning

confidence: 99%

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Huang¹,

Liu²

2023

Clin Mol Hepatol

View full text Add to dashboard Cite

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma (HCC), its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex.The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population.

show abstract

“…However, since MAFLD patients could have other concomitant liver diseases such as alcohol, viral hepatitis, or autoimmune liver diseases etc., the natural history and clinical outcomes of those patients need further investigations. 30…”

Section: Discussionmentioning

confidence: 99%

Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications

2022

Self Cite

View full text Add to dashboard Cite

Background/purpose:A nomenclature of "metabolic associated fatty liver disease" (MAFLD) with new de nition was proposed in 2020 instead of previous "non-alcoholic fatty liver disease" (NAFLD). However, which better ts the clinical demand remains controversial. MethodsThe participants with fatty liver on ultrasonography from Taiwan bio-bank cohort were included. MAFLD was de ned as the presence of fatty liver, plus any of the following three conditions: overweight/obesity, type 2 diabetes mellitus (DM), or metabolic dysfunction. The severity of liver brosis was determined using brosis-4 (FIB-4) score and NAFLD brosis score (NFS). The risk of atherosclerosis was assessed using intima media thickness (IMT) or plaques of carotid duplex ultrasound. ResultsA total of 9719 subjects (age 55.9 ± 10.8; males 42.6%) were divided to four groups including "both fatty liver disease (FLD)", "MAFLD only", "NAFLD only", and "neither FLD" with the percentages of 79.7%, 12%, 7.1%, and 1.2%, respectively. Compared with NAFLD patients, MAFLD patients had higher frequency of male gender, BMI, waist circumference, HbA1C, and triglyceride. On addition, they had higher levels of serum ALT, AST, GGT, fatty liver index (FLI), NFS and IMT, but no difference in FIB-4 index and the percentage of carotid plaques. Of note, the added population "MAFLD only group" had higher levels of AST, ALT, GGT, FLI, FIB-4, NFS, IMT and higher percentage of carotid plaques than the missed population "NAFLD only group". ConclusionsThis large, population-based study showed MAFLD with new diagnostic criteria could identify more highrisk patients of metabolic, liver and cardiovascular disease complications in clinical practice.

show abstract

Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B

Cited by 16 publications

References 30 publications

Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease

Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications

Contact Info

Product

Resources

About